115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pelabresib (CPI-0610) improved anemia associated with myelofibrosis: Interim results from the ongoing MANIFEST phase 2 study
    Meeting Abstract

    Bose, P.; Verstovsek, S.; Kremyanskaya, M.; Mascarenhas, J.; Talpaz, M.; Harrison, C.; Rampal, R.; Patriarca, A.; Gupta, V.; Granacher, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Clinical benefit of pelabresib (CPI-0610) in combination with ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis patients: Interim efficacy subgroup analysis from Arm 3 of the MANIFEST phase 2 study
    Meeting Abstract

    Gupta, V.; Kremyanskaya, M.; Mascarenhas, J.; Palandri, F.; Patriarca, A.; Devos, T.; Harrison, C.; Passamonti, F.; Rampal, R.; Mead, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • The BET inhibitor pelabresib decreases inflammatory cytokines, improves bone marrow fibrosis and function, and demonstrates clinical response irrespective of mutation status in myelofibrosis patients in the phase 2 MANIFEST trial
    Meeting Abstract

    Zavidij, O.; Keller, P.; Cui, J. K.; Mertz, J.; Salama, M.; Olteanu, H.; Chiu, A.; Chen, D.; Hanson, C. A.; Chen, Z. H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Asciminib provides durable responses and a favorable safety profile in patients with chronic myeloid leukemia (CML) in chronic phase (CP) with the T315I mutation in a phase 1 study
    Meeting Abstract

    Cortes, J. E.; Hughes, T. P.; Mauro, M. J.; Hochhaus, A.; Réa, D.; Goh, Y. T.; Janssen, J. J. W. M.; Heinrich, M. C.; Talpaz, M.; Etienne, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Ivosidenib (IVO) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment for the MDS sub-study
    Meeting Abstract

    DiNardo, C. D.; Foran, J. M.; Watts, J. M.; Stein, E. M.; de Botton, S.; Fathi, A. T.; Prince, G. T.; Stein, A. S.; Stone, R. M.; Patel, P. A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Add-on parsaclisib (a PI3K5 inhibitor) in patients with myelofibrosis and suboptimal response to ruxolitinib: Interim analysis from a phase 2 study
    Meeting Abstract

    Yacoub, A.; Borate, U.; Rampal, R.; Ali, H.; Wang, E.; Gerds, A.; Hobbs, G.; Kremyanskaya, M.; Winton, E.; O'Connell, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • ASCEMBL phase 3 health-related quality of life (HRQL) comparison of asciminib and bosutinib for patients with chronic myelogenous leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors (TKI)
    Meeting Abstract

    Mauro, M. J.; Boquimpani, C.; Rea, D.; Hochhaus, A.; Maheshwari, V. K.; Allepuz, A.; Patwardhan, P.; Wu, Y.; DeRosa, M.; Minami, Y.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Insights from the informCLL registry: Real-world application of NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Meeting Abstract

    Ghosh, N.; Brander, D.; Mato, A. R.; Sharman, J. P.; Gutierrez, M.; Naganuma, M.; Upasani, S.; Alagappan, D.; Huang, Q.; Young, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Effect of comorbidities on response outcomes with first-line tyrosine kinase inhibitors (TKIs), dasatinib versus imatinib, in patients with chronic myeloid leukemia in chronic phase (CML-CP): Exploratory post hoc analysis of DASISION
    Meeting Abstract

    Breccia, M.; Mauro, M.; Jabbour, E.; Saglio, G.; Jiménez-Velasco, A.; le Coutre, P.; DeGutis, I.; Khan, W.; Sy, O.; Swanink, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON)
    Meeting Abstract

    Cortes, J. E.; Apperley, J. F.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save